Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment

Szilvia Vas, Zita Kátai, Diána Kostyalik, Dorottya Pap, Eszter Molnár, Péter Petschner, L. Kalmár, G. Bagdy

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The effects of the widely used selective serotonin reuptake inhibitor (SSRI) antidepressants on sleep have been intensively investigated. However, only a few animal studies examined the effect of escitalopram, the more potent S-enantiomer of citalopram, and conclusions of these studies on sleep architecture are limited due to the experimental design. Here, we investigate the acute (2 and 10 mg/kg, i.p. injected at the beginning of the passive phase) or chronic (10 mg/kg/day for 21 days, by osmotic minipumps) effects of escitalopram on the sleep and quantitative electroencephalogram (EEG) of Wistar rats. The first 3 h of EEG recording was analyzed at the beginning of passive phase, immediately after injections. The acutely injected 2 and 10 mg/kg and the chronically administered 10 mg/kg/day escitalopram caused an approximately three, six and twofold increases in rapid eye movement sleep (REMS) latency, respectively. Acute 2-mg/kg escitalopram reduced REMS, but increased intermediate stage of sleep (IS) while the 10 mg/kg reduced both. We also observed some increase in light slow wave sleep and passive wake parallel with a decrease in deep slow wave sleep and theta power in both active wake and REMS after acute dosing. Following chronic treatment, only the increase in REMS latency remained significant compared to control animals. In conclusion, adaptive changes in the effects of escitalopram, which occur after 3 weeks of treatment, suggest desensitization in the function of 5-HT1A and 5-HT1B receptors.

Original languageEnglish
Pages (from-to)169-176
Number of pages8
JournalJournal of Neural Transmission
Volume120
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Citalopram
REM Sleep
Sleep
Therapeutics
Electroencephalography
Receptor, Serotonin, 5-HT1B
Power (Psychology)
Sleep Stages
Serotonin Uptake Inhibitors
Antidepressive Agents
Wistar Rats
Research Design
Light
Injections

Keywords

  • 5-HT receptor
  • Chronic treatment
  • Escitalopram
  • Intermediate stage of sleep
  • Rapid eye movement (REM) sleep
  • SSRI

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment. / Vas, Szilvia; Kátai, Zita; Kostyalik, Diána; Pap, Dorottya; Molnár, Eszter; Petschner, Péter; Kalmár, L.; Bagdy, G.

In: Journal of Neural Transmission, Vol. 120, No. 1, 01.2013, p. 169-176.

Research output: Contribution to journalArticle

Vas, Szilvia ; Kátai, Zita ; Kostyalik, Diána ; Pap, Dorottya ; Molnár, Eszter ; Petschner, Péter ; Kalmár, L. ; Bagdy, G. / Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment. In: Journal of Neural Transmission. 2013 ; Vol. 120, No. 1. pp. 169-176.
@article{37ee4897d9454a7da8ea65f03b9eced6,
title = "Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment",
abstract = "The effects of the widely used selective serotonin reuptake inhibitor (SSRI) antidepressants on sleep have been intensively investigated. However, only a few animal studies examined the effect of escitalopram, the more potent S-enantiomer of citalopram, and conclusions of these studies on sleep architecture are limited due to the experimental design. Here, we investigate the acute (2 and 10 mg/kg, i.p. injected at the beginning of the passive phase) or chronic (10 mg/kg/day for 21 days, by osmotic minipumps) effects of escitalopram on the sleep and quantitative electroencephalogram (EEG) of Wistar rats. The first 3 h of EEG recording was analyzed at the beginning of passive phase, immediately after injections. The acutely injected 2 and 10 mg/kg and the chronically administered 10 mg/kg/day escitalopram caused an approximately three, six and twofold increases in rapid eye movement sleep (REMS) latency, respectively. Acute 2-mg/kg escitalopram reduced REMS, but increased intermediate stage of sleep (IS) while the 10 mg/kg reduced both. We also observed some increase in light slow wave sleep and passive wake parallel with a decrease in deep slow wave sleep and theta power in both active wake and REMS after acute dosing. Following chronic treatment, only the increase in REMS latency remained significant compared to control animals. In conclusion, adaptive changes in the effects of escitalopram, which occur after 3 weeks of treatment, suggest desensitization in the function of 5-HT1A and 5-HT1B receptors.",
keywords = "5-HT receptor, Chronic treatment, Escitalopram, Intermediate stage of sleep, Rapid eye movement (REM) sleep, SSRI",
author = "Szilvia Vas and Zita K{\'a}tai and Di{\'a}na Kostyalik and Dorottya Pap and Eszter Moln{\'a}r and P{\'e}ter Petschner and L. Kalm{\'a}r and G. Bagdy",
year = "2013",
month = "1",
doi = "10.1007/s00702-012-0847-2",
language = "English",
volume = "120",
pages = "169--176",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment

AU - Vas, Szilvia

AU - Kátai, Zita

AU - Kostyalik, Diána

AU - Pap, Dorottya

AU - Molnár, Eszter

AU - Petschner, Péter

AU - Kalmár, L.

AU - Bagdy, G.

PY - 2013/1

Y1 - 2013/1

N2 - The effects of the widely used selective serotonin reuptake inhibitor (SSRI) antidepressants on sleep have been intensively investigated. However, only a few animal studies examined the effect of escitalopram, the more potent S-enantiomer of citalopram, and conclusions of these studies on sleep architecture are limited due to the experimental design. Here, we investigate the acute (2 and 10 mg/kg, i.p. injected at the beginning of the passive phase) or chronic (10 mg/kg/day for 21 days, by osmotic minipumps) effects of escitalopram on the sleep and quantitative electroencephalogram (EEG) of Wistar rats. The first 3 h of EEG recording was analyzed at the beginning of passive phase, immediately after injections. The acutely injected 2 and 10 mg/kg and the chronically administered 10 mg/kg/day escitalopram caused an approximately three, six and twofold increases in rapid eye movement sleep (REMS) latency, respectively. Acute 2-mg/kg escitalopram reduced REMS, but increased intermediate stage of sleep (IS) while the 10 mg/kg reduced both. We also observed some increase in light slow wave sleep and passive wake parallel with a decrease in deep slow wave sleep and theta power in both active wake and REMS after acute dosing. Following chronic treatment, only the increase in REMS latency remained significant compared to control animals. In conclusion, adaptive changes in the effects of escitalopram, which occur after 3 weeks of treatment, suggest desensitization in the function of 5-HT1A and 5-HT1B receptors.

AB - The effects of the widely used selective serotonin reuptake inhibitor (SSRI) antidepressants on sleep have been intensively investigated. However, only a few animal studies examined the effect of escitalopram, the more potent S-enantiomer of citalopram, and conclusions of these studies on sleep architecture are limited due to the experimental design. Here, we investigate the acute (2 and 10 mg/kg, i.p. injected at the beginning of the passive phase) or chronic (10 mg/kg/day for 21 days, by osmotic minipumps) effects of escitalopram on the sleep and quantitative electroencephalogram (EEG) of Wistar rats. The first 3 h of EEG recording was analyzed at the beginning of passive phase, immediately after injections. The acutely injected 2 and 10 mg/kg and the chronically administered 10 mg/kg/day escitalopram caused an approximately three, six and twofold increases in rapid eye movement sleep (REMS) latency, respectively. Acute 2-mg/kg escitalopram reduced REMS, but increased intermediate stage of sleep (IS) while the 10 mg/kg reduced both. We also observed some increase in light slow wave sleep and passive wake parallel with a decrease in deep slow wave sleep and theta power in both active wake and REMS after acute dosing. Following chronic treatment, only the increase in REMS latency remained significant compared to control animals. In conclusion, adaptive changes in the effects of escitalopram, which occur after 3 weeks of treatment, suggest desensitization in the function of 5-HT1A and 5-HT1B receptors.

KW - 5-HT receptor

KW - Chronic treatment

KW - Escitalopram

KW - Intermediate stage of sleep

KW - Rapid eye movement (REM) sleep

KW - SSRI

UR - http://www.scopus.com/inward/record.url?scp=84872316905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872316905&partnerID=8YFLogxK

U2 - 10.1007/s00702-012-0847-2

DO - 10.1007/s00702-012-0847-2

M3 - Article

C2 - 22729519

AN - SCOPUS:84872316905

VL - 120

SP - 169

EP - 176

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 1

ER -